DRKS00016679已完成2 期
A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome) - FFA-MAE
niversitätsklinikum Schleswig-Holstein, Klinik für Kinder- und Jugendmedizin II, Abteilung für Neuropädiatrie und Sozialpädiatrie0 个研究点目标入组 10 人开始时间: 2019年11月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 1 Years 至 18 Years（—）
- 性别
- All
入选标准
- •Diagnosis of Doose syndrome
- •Age: 1 to 18 years.
- •Normal neurological development before the onset of epilepsy and absence of organic cerebral abnormalities.
- •Onset of myoclonic, myoclonic-(atonic) astatic or atonic-astatic seizures, absences, status of „petit mal, generalized tonic clonic seizures; sometimes febrile seizures occur before the start of epilepsy.
- •Multiple seizure types (at least 2) including in any case myoclonic atonic seizures
- •at least 6 documented seizures in the last 4 weeks before inclusion
- •on >= 1AED during the 4 weeks before inclusion
- •Presence on EEG of biparietal theta background rhythm, and irregularly generalized spike wave, and polyspike wave
排除标准
- •Any cardiovascular abnormality
- •Abnormal weight
- •Cortical structural brain lesions.
- •Presence of severe and benign myoclonic epilepsy (SME, BME) in infancy and early childhood
- •Presence of cryptogenic Lennox-Gastaut syndrome, based on the ILAE definitions
- •Presence of atypical benign partial epilepsy/pseudo-Lennox-syndrome
- •Presence of other symptomatic / cryptogenic epilepsies (e.g. with a frontal lobe semiology).
- •Progressive neurodegenerative disease
- •certain drugs
研究者
相似试验
进行中（未招募）
1 期
An Investigation to see if the investigational product ZX008 (fenfluramine hydrochloride) contributes to reducing the incidence of seizures in children and young adults with Doose syndrome, an early childhood form of epilepsy.Childhood epilepsy: Myoclonic Astatic Epilepsy (Doose-Syndrome)MedDRA version: 20.1Level: LLTClassification code 10015040Term: Epilepsy equivalentSystem Organ Class: 100000004852EUCTR2018-001664-38-DEniversity Hospital Schleswig-Holstein (UKSH)10
已完成
不适用
Prospective evaluation of determining the most effective contact for tremor control in patients with deep brain stimulation based on individual tractographyESSENTIAL TREMORParkinson's DiseaseDRKS00026596niversität zu KölnZentrum für Klinische Studien40
进行中（未招募）
1 期
A PROOF OF CONCEPT STUDY TO EVALAUTE EFFECTS INTRANASAL SALMETEROL AND FLUTICASONE GIVEN ALONE AND IN COMBINATION IN ALLERGIC RHINITIS - Effects of Intranasal Salmeterol and Fluticasone in Allergic RhinitisAllergic RhinitisEUCTR2005-005523-34-GBniversity of Dundee (Research & Innovation Services)30
进行中（未招募）
1 期
Proof of concept study of the efficacy and tolerability of a 4 week treatment with F13640 in patients in whom the adaptation of opioid therapy of cancer pain has failed - NDEUCTR2007-003249-34-ITPierre Fabre Medicament72
进行中（未招募）
不适用
Proof of Concept study of the efficacy and tolerability of a 4-week treatment with F13640 in patients in whom the adaptation of opioid therapy of cancer pain has failed. A prospective, multinational, multicentre, randomised, double-blind, placebo-controlled study.EUCTR2007-003249-34-BEPIERRE FABRE MEDICAMENT72